The research group leading this project continues the study of analogous compounds of trimethylangelicin (TMA), a natural substance with anti-inflammatory properties. The results obtained in the FFC pilot project FFC#22/2019 provide a valid motivation to extend the development of one of these analogous compounds, the GY971a that showed to have the activity of corrector of defective CFTR in addition to its anti-inflammatory properties. The goal of the project is therefore to proceed with the preclinical analysis of GY971a, as a potential anti-inflammatory agent and corrector of mutated CFTR. This derivative will be evaluated in primary HBE cells derived from CF patients (epithelia obtained by the Servizio Colture Primarie) and in murine models of chronic inflammation (treatments and analyzes conducted in collaboration with CFaCore). With this project we want to increase the possible therapeutic avenues to counteract inflammation in CF, developing a new anti-inflammatory at the preclinical level.